Reply to: Dose- and exposure-response to ketamine in depression

James W. Murrough; James M. Gallo; Katherine A. Collins; Marije Aan Het Rot; Dennis S. Charney

doi:10.1016/j.biopsych.2011.02.018

Reply to: Dose- and exposure-response to ketamine in depression

James W. Murrough, James M. Gallo, Katherine A. Collins, Marije Aan Het Rot, Dennis S. Charney

Research output: Contribution to journal › Letter › peer-review

4 Scopus citations

Original language	English
Pages (from-to)	e11-e12
Journal	Biological Psychiatry
Volume	70
Issue number	4
DOIs	https://doi.org/10.1016/j.biopsych.2011.02.018
State	Published - 15 Aug 2011

Access to Document

10.1016/j.biopsych.2011.02.018

Cite this

@article{2d0191250b2040c09977aa3a6ebe13dd,

title = "Reply to: Dose- and exposure-response to ketamine in depression",

author = "Murrough, {James W.} and Gallo, {James M.} and Collins, {Katherine A.} and {Aan Het Rot}, Marije and Charney, {Dennis S.}",

note = "Funding Information: Dr. Murrough receives research support from the National Alliance for Research on Schizophrenia and Depression and salary support from a research education grant from AstraZeneca to Mount Sinai School of Medicine. Dr. Charney has been named as an inventor on a use-patent of ketamine for the treatment of depression. If ketamine were shown to be effective in the treatment of depression and received approval from the U.S. Food and Drug Administration for this indication, Dr. Charney and the Mount Sinai School of Medicine could benefit financially. All other authors reported no biomedical financial interests or potential conflicts of interest.",

year = "2011",

month = aug,

day = "15",

doi = "10.1016/j.biopsych.2011.02.018",

language = "English",

volume = "70",

pages = "e11--e12",

journal = "Biological Psychiatry",

issn = "0006-3223",

publisher = "Elsevier USA",

number = "4",

}

TY - JOUR

T1 - Reply to

T2 - Dose- and exposure-response to ketamine in depression

AU - Murrough, James W.

AU - Gallo, James M.

AU - Collins, Katherine A.

AU - Aan Het Rot, Marije

AU - Charney, Dennis S.

N1 - Funding Information: Dr. Murrough receives research support from the National Alliance for Research on Schizophrenia and Depression and salary support from a research education grant from AstraZeneca to Mount Sinai School of Medicine. Dr. Charney has been named as an inventor on a use-patent of ketamine for the treatment of depression. If ketamine were shown to be effective in the treatment of depression and received approval from the U.S. Food and Drug Administration for this indication, Dr. Charney and the Mount Sinai School of Medicine could benefit financially. All other authors reported no biomedical financial interests or potential conflicts of interest.

PY - 2011/8/15

Y1 - 2011/8/15

UR - http://www.scopus.com/inward/record.url?scp=79960780652&partnerID=8YFLogxK

U2 - 10.1016/j.biopsych.2011.02.018

DO - 10.1016/j.biopsych.2011.02.018

M3 - Letter

AN - SCOPUS:79960780652

SN - 0006-3223

VL - 70

SP - e11-e12

JO - Biological Psychiatry

JF - Biological Psychiatry

IS - 4

ER -